Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Nov. 13, 2024 -- People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns.
Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing schizophrenia compared to the general population, Canadian researchers report.
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased risk of schizophrenia after ER treatment for psychedelic use.
Hallucinogens include drugs like psilocybin, LSD, DMT (Ayahuasca) and MDMA (Ecstasy).
“Our findings underscore a concerning link between hallucinogen use that requires care in the emergency room and increased risk of schizophrenia,” said investigator Dr. Daniel Myran, research chair in social accountability at the University of Ottawa.
“While there is enormous enthusiasm for psychedelic-assisted therapy as a new mental health treatment, we need to remember how early and limited the data remains for both the benefits and the risks,” Myran added in a university news release.
For the study, researchers analyzed health data for more than 9.2 million people ages 14 to 65 living in Ontario between 2008 and 2021.
Researchers looked at emergency room visits involving hallucinogens, and whether patients had been diagnosed with schizophrenia afterward.
Overall, annual rates of ER visits involving hallucinogens increased by 86% between 2014 and 2021, after remaining stable from 2008 to 2012, results show.
About 4% of people were diagnosed with schizophrenia within three years of an ER visit involving hallucinogens, researchers found. By comparison, only 0.15% of the general population developed schizophrenia during the study period.
People with ER visits for psychedelics also were more likely to develop schizophrenia than those who visited the ER due to alcohol (4.7 times greater) or cannabis (1.5 times greater).
However, researchers noted that the findings cannot prove a cause-and-effect link between hallucinogen use and schizophrenia, and that more study is needed to better understand this relationship.
“Clinical trials of psychedelic-assisted psychotherapy have safeguards, such as excluding individuals with a personal or family history of schizophrenia and close monitoring while participants use hallucinogens,” Myran said. “Our findings provide a timely caution about potential risks of hallucinogen use outside of trial settings.”
The researchers also noted it’s important that ER doctors treating patients who’ve used psychedelics be aware of the mental health risks these folks face.
The new study was published Nov. 13 in the journal JAMA Psychiatry.
Sources
- University of Ottawa, news release, Nov. 13, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Trump's Surgeon General Pick Touts Psychedelics for Health
THURSDAY, May 15, 2025 — President Donald Trump's choice for U.S. surgeon general has raised eyebrows for promoting the use of psychedelic drugs, such as psilocybin, in a...
CDC: Drug Overdose Deaths Down More Than 25 Percent in 2024
WEDNESDAY, May 14, 2025 -- Drug overdose deaths decreased by 26.9 percent from 2023 to 2024, according to provisional data released today from the National Center for Health...
Medicaid 'Unwinding' Cost Kids Access To Asthma Inhalers, Other Chronic Disease Meds
MONDAY, May 12, 2025 — Children and young adults formerly covered by Medicaid are losing access to medications needed to control conditions like depression, schizophrenia...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.